Sab Biotherapeutics Inc's Customers Performance

Name: Sab Biotherapeutics Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

SABS

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


SABS's Source of Revenues		• List of SABS Customers

for the same period Sab Biotherapeutics Inc

• List of SABS Customers

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Sab Biotherapeutics Inc's Comment on Sales, Marketing and Customers

The company focuses on treatments and clinical investigations for Type 1 Diabetes (T1D), targeting patients across Stages 1 to 4, with particular emphasis on Stage 2 and Stage 3 T1D. Its FDA-approved drug, Tzield (teplizumab), is indicated to delay the onset of T1D in patients exhibiting two or more diabetes-related auto-antibodies and holds approval in both the U.S. and EU for Stage 2 T1D. Tzield is also under regulatory review for approval in Stage 3 T1D. The company addresses unmet medical needs for therapies aimed at new onset Stage 3 T1D patients. Clinical trials, including the Phase 2 TN19 trial conducted at the University of Florida, have evaluated low-dose rabbit anti-thymocyte globulin (rATG) for preserving C-peptide levels and delaying disease progression in new onset T1D patients. The company acknowledges challenges related to treatment burden and immunogenicity associated with current therapies.

Sab Biotherapeutics Inc’s Comment on Sales, Marketing and Customers

SABS's Stock Performance relative to it's Customers

SABS's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Sab Biotherapeutics Inc	270.36	58.72	-0.40	86
SUBTOTAL	0.00	0.00	0.00	-

Sources: Sab Biotherapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Sab Biotherapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Sab Biotherapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.